NASDAQ:CDNA

CareDx (CDNA) Stock Price, News & Analysis

$8.23
+0.06 (+0.73%)
(As of 04/23/2024 ET)
Today's Range
$8.15
$8.76
50-Day Range
$7.85
$12.08
52-Week Range
$4.80
$12.93
Volume
448,610 shs
Average Volume
899,133 shs
Market Capitalization
$426.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.50

CareDx MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
64.0% Upside
$13.50 Price Target
Short Interest
Bearish
10.48% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.66
Upright™ Environmental Score
News Sentiment
0.59mentions of CareDx in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.59) to ($1.17) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.35 out of 5 stars

Medical Sector

287th out of 909 stocks

Medical Laboratories Industry

8th out of 19 stocks

CDNA stock logo

About CareDx Stock (NASDAQ:CDNA)

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

CDNA Stock Price History

CDNA Stock News Headlines

CareDx (NASDAQ:CDNA) Stock Rating Reaffirmed by Stephens
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
CDNA Apr 2024 10.000 put
CDNA Apr 2024 2.500 call
CDNA Mar 2024 17.500 call
CareDx, Inc (NASDAQ:CDNA) Q4 2023 Earnings Call Transcript
Earnings Outlook For CareDx
CareDx Stock (NASDAQ:CDNA), Short Interest Report
See More Headlines
Receive CDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/23/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:CDNA
Employees
635
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.50
High Stock Price Target
$15.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+64.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-190,280,000.00
Pretax Margin
-67.83%

Debt

Sales & Book Value

Annual Sales
$280.32 million
Book Value
$4.83 per share

Miscellaneous

Free Float
49,604,000
Market Cap
$426.15 million
Optionable
Optionable
Beta
1.42
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Abhishek Jain (Age 47)
    CFO & Principal Accounting Officer
    Comp: $425.58k
  • Dr. Peter Maag Ph.D. (Age 57)
    Executive Director
    Comp: $43.23k
  • Mr. Alexander L. Johnson (Age 50)
    President of Patient & Testing Services
    Comp: $547.43k
  • Ms. Marica Grskovic Ph.D.
    Chief Operating Officer
  • Dr. Robert N. Woodward Ph.D.
    Chief Scientific Officer
  • Mr. GS Jha
    Senior VP, Chief Information Officer & Chief Information Security Officer
  • Mr. Ian Cooney
    Vice President of Investor Relations
  • Jeffrey A. Novack
    General Counsel
  • Ms. Stacey Follon
    Senior VP & Head of Human Resources
  • Mr. Kashif Rathore
    Chief of Patient & Digital Solutions

CDNA Stock Analysis - Frequently Asked Questions

Should I buy or sell CareDx stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CDNA shares.
View CDNA analyst ratings
or view top-rated stocks.

What is CareDx's stock price target for 2024?

4 equities research analysts have issued 12-month price objectives for CareDx's stock. Their CDNA share price targets range from $12.00 to $15.00. On average, they expect the company's stock price to reach $13.50 in the next twelve months. This suggests a possible upside of 64.0% from the stock's current price.
View analysts price targets for CDNA
or view top-rated stocks among Wall Street analysts.

How have CDNA shares performed in 2024?

CareDx's stock was trading at $12.00 at the beginning of 2024. Since then, CDNA stock has decreased by 31.4% and is now trading at $8.23.
View the best growth stocks for 2024 here
.

When is CareDx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our CDNA earnings forecast
.

How were CareDx's earnings last quarter?

CareDx, Inc (NASDAQ:CDNA) posted its quarterly earnings results on Wednesday, February, 28th. The company reported ($2.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $1.97. The firm had revenue of $65.57 million for the quarter, compared to the consensus estimate of $63.66 million. CareDx had a negative net margin of 67.88% and a negative trailing twelve-month return on equity of 51.40%. The firm's revenue for the quarter was down 20.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.34) earnings per share.

What ETFs hold CareDx's stock?

ETFs with the largest weight of CareDx (NASDAQ:CDNA) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) and Jacob Forward ETF (JFWD).Global X Genomics & Biotechnology ETF (GNOM).

What guidance has CareDx issued on next quarter's earnings?

CareDx updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $260.0 million-$274.0 million, compared to the consensus revenue estimate of $260.6 million.

What other stocks do shareholders of CareDx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Block (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Enphase Energy (ENPH), Johnson & Johnson (JNJ), Activision Blizzard (ATVI) and Alibaba Group (BABA).

Who are CareDx's major shareholders?

CareDx's stock is owned by a variety of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (5.31%), Los Angeles Capital Management LLC (0.50%) and Allspring Global Investments Holdings LLC (0.04%). Insiders that own company stock include Ankur Dhingra, George Bickerstaff, Grace Colon, Michael Goldberg, Paul Adler, Peter Maag, Ralph Snyderman, Reginald Seeto, Sasha King, Thomas A Thomas and William A Hagstrom.
View institutional ownership trends
.

How do I buy shares of CareDx?

Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CDNA) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners